Chemical Component Summary

NameISO-URSODEOXYCHOLIC ACID
Identifiers(4R)-4-[(3S,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
FormulaC24 H40 O4
Molecular Weight392.572
TypeNON-POLYMER
Isomeric SMILESC[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@@H](C4)O)C)O)C
InChIInChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16+,17-,18+,19+,20+,22+,23+,24-/m1/s1
InChIKeyRUDATBOHQWOJDD-DNMBCGTGSA-N

Chemical Details

Formal Charge0
Atom Count68
Chiral Atom Count10
Bond Count71
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB01586 
NameUrsodeoxycholic acid
Groups
  • approved
  • investigational
DescriptionUrsodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool.[A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years.[A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by 7b-epimerization of [chenodeoxycholic acid], which is a primary bile acid.[A256272] Due to its hydrophilicity, UDCA is less toxic than [cholic acid] or [chenodeoxycholic acid].[A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.[A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272]
Synonyms
  • Acido ursodeossicolico
  • Acido ursodeoxicolico
  • 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
  • (3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
  • Ursodiol
Brand Names
  • Urso 250
  • BAMBOO SALT Eunganggo Jook Yeom Toothpaste
  • Dom-ursodiol C
  • Ursodiol 400 mg
  • Mint-ursodiol
IndicationUrsodeoxycholic acid is indicated for the treatment of patients with primary biliary cholangitis.[L44627] It is used for the short-term treatment of radiolucent, noncalcified gallbladder stones in patients selected for elective cholecystectomy. It is also used to prevent gallstone formation in obese patients experiencing rapid weight loss.[L44793]
Categories
  • Alimentary Tract and Metabolism
  • Bile Acid Preparations
  • Bile acids and derivatives
  • Bile Acids and Salts
  • Bile and Liver Therapy
ATC-CodeA05AA02
CAS number128-13-2

Drug Targets

NameTarget SequencePharmacological ActionActions
Aldo-keto reductase family 1 member C2MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHID...unknowninhibitor
Bile acid receptorMVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQN...unknownpartial agonist
Cytochrome P450 3A SubfamilyMALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknowninducer
Bile salt export pumpMSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQL...unknownsubstrate,inhibitor,inducer
Solute carrier organic anion transporter family member 1A2MGETEKRIETHRIRCLSKLKMFLLAITCAFVSKTLSGSYMNSMLTQIERQ...unknownsubstrate,inhibitor,inducer
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 127601
ChEMBL CHEMBL1233687
ChEBI CHEBI:43419
CCDC/CSD NECPUG